Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article (0)
Advertisement

ResearchIn-Press PreviewCell biologyOncology Open Access | 10.1172/jci.insight.186703

Lomitapide enhances cytotoxic effects of temozolomide in chemo-resistant glioblastoma

Alyona Ivanova,1 Taylor M. Wilson,1 Kimia Ghannad-Zadeh,1 Esmond Tse,1 Robert Flick,2 Megan Wu,1 and Sunit Das1

1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada

2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada

3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America

Find articles by Ivanova, A. in: PubMed | Google Scholar

1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada

2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada

3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America

Find articles by Wilson, T. in: PubMed | Google Scholar

1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada

2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada

3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America

Find articles by Ghannad-Zadeh, K. in: PubMed | Google Scholar

1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada

2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada

3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America

Find articles by Tse, E. in: PubMed | Google Scholar

1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada

2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada

3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America

Find articles by Flick, R. in: PubMed | Google Scholar

1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada

2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada

3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America

Find articles by Wu, M. in: PubMed | Google Scholar

1The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, Canada

2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada

3The Arthur and Sonia Labatt Brain Tumour Research Center, The Hospital for Sick Children, Toronto, United States of America

Find articles by Das, S. in: PubMed | Google Scholar |

Published July 23, 2025 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.186703.
Copyright © 2025, Ivanova et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 23, 2025 - Version history
View PDF
Abstract

More than one third of patients with glioblastoma experience tumour progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier that to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma. In vitro treatment of temozolomide-resistant glioblastoma cells with lomitapide resulted in decreased intracellular ubiquinone levels and sensitized cells to temozolomide-induced ferroptosis. Concomitant treatment with lomitapide and temozolomide (TMZ) prolonged survival and delayed tumour recurrence in a mouse glioblastoma model, compared to treatment with TMZ alone. Our data identified lomitapide as a potential adjunct for treatment of temozolomide-resistant glioblastoma.

Graphical Abstract
graphical abstract
Supplemental material

View Unedited blot and gel images

View

Version history
  • Version 1 (July 23, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (0)

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts